8E11-CPT2

8E11-CPT2 is an experimental agent referenced in preclinical cancer research as part of a combination therapy for RAS mutant colorectal cancer. In published abstracts, 8E11-CPT2 is investigated in combination with cetuximab (CTX), showing significant reduction in tumor burden in patient-derived xenograft models. The specific molecular nature of 8E11-CPT2—such as whether it is a small molecule, antibody, or other biological—is not described in publicly available sources. No approved indications, advanced clinical development, or detailed mechanism of action have been disclosed in the literature as of this date[1].